Pathways and Inborn Errors of Bile Acid Synthesis

Bile acids are synthesized from cholesterol through 17 different enzymes located in different intracellular compartments of hepatocytes. Defects have been identified in the genes encoding the enzymes involved in the bile acid synthesis pathways and nine different diseases have been identified so far. In this review, four different biosynthetic pathways of bile acids together with disorders of bile acid synthesis are described. In inborn errors of bile acid synthesis clinical findings can range from liver failure to cirrhosis in infancy or progressive neuropathy in adolescence / adulthood. Laboratory analysis of urine profiling of bile acids is important in early diagnosis and early treatment.

Kaynakça

[1] Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile Acid Physiology. Ann Hepatol 2017; 16: 4-14.

[2] Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7(8): 678-93.

[3] Ikegami T, Honda AN. Reciprocal interactions between bile acids and gut microbiota in human liver diseases. Hepatol Res 2018; 48(1): 15-27.

[4] Martinot E, Sèdes L, Baptissart M, et al. Bile acids and their receptors. Mol Aspects Med 2017; 56: 2-9.

[5] Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 2011; 11(3): 160-6.

[6] Degirolamo C, Rainaldi S, Bovenga F, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 2014; 10; 7(1): 12-8.

[7] Pavlidis P, Powell N, Vincent RP, et al. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Aliment Pharmacol Ther 2015; 42(7): 802-17.

[8]Chiang JYL, Ferrell JM. Bile Acid Metabolism in Liver Pathobiology. Gene Expr 2018; 18; 18(2): 71-87.

[9] Eggert T, Bakonyi D, Hummel W. Enzymatic routes for the synthesis of ursodeoxycholic acid. J Biotechnol 2014; 10; 191:11-21.

[10] Hofmann AF, Mysels KJ. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res 1992; 33 (5): 617-26.

[11] Walker IA, Nelson-Piercy C, Williamson C. Role of bile acid measurement in pregnancy. Ann Clin Biochem 2002; 39 (Pt 2):105-13.

[12]Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci 2009; 14: 2584–2598.

[13] Borelli G. De Motu animalium, Pars altera. Angeli Bernabo, Rome. English translation by P. Gosse, The Hague, Netherlands. 1743. Reprinted in 1989 by Springer, Berlin. 1681; 354–364.

[14] Chiang JY. Recent advances in understanding bile acid homeostasis. F1000Res 2017; 20; 6: 2029.

[15] Gonzalez FJ. Nuclear receptor control of enterohepatic circulation. Compr Physiol 2012; 2(4): 2811-28.

[16]Mertens KL, Kalsbeek A, Soeters MR, et al. Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System. Front Neurosci 2017; 7; 11: 617.

[17] Dawson PA and Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res 2015; 56(6): 1085–1099.

[18] Šarenac TM, Mikov M. Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients. Front Pharmacol 2018; 25; 9: 939.

[19] Vaz FM, Ferdinandusse S. Bile acid analysis in human disorders of bile acid biosynthesis. Mol Aspects Med 2017; 56: 10-24.

[29] Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med 2007; 7(2): 199-218.

[21] Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72:137-74.

[22] Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 2004; 40(3): 539-51.

[23] Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50(10): 1955-66.

[24] Björkhem I, Leoni V, Meaney S. Genetic connections between neurological disorders and cholesterol metabolism. J Lipid Res 2010; 51(9): 2489-503.

[25] Axelson M, Sjövall J. Potential bile acid precursors in plasma--possible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man. J Steroid Biochem 1990; 28; 36(6): 631-40.

[26] Boyer JL. Bile formation and secretion. Compr Physiol 2013; 3(3): 1035-78.

[27] Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014; 66(4): 948-83.

[28] Hylemon P, Zhou H, Pandak WM, et al. Bile acids as regulatory molecules. J Lipid Res 2009; 50(8): 1509-20.

[29] Ellis EC. Suppression of bile acid synthesis by thyroid hormone in primary human hepatocytes. World J Gastroenterol 2006; 7; 12(29): 4640-5.

[30] De Fabiani E, Mitro N, Anzulovich AC, et al. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J Biol Chem 2001; 17; 276(33): 30708-16.

[31] Björkhem I, Diczfalusy U. Oxysterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol 2002; 1; 22(5): 734-42.

[32] Setchell KD, Dumaswala R, Colombo C, et al. Hepatic bile acid metabolism during early development revealed from the analysis of human fetal gallbladder bile. J Biol Chem 1988; 15; 263(32): 16637-44.

[33] Kevresan S, Kuhajda K, Kandrac J, et al. Biosynthesis of bile acids in mammalian liver. Eur J Drug Metab Pharmacokinet 2006; 31(3): 145-56.

[34] Nakagawa M, Setchell KD. Bile acid metabolism in early life: studies of amniotic fluid. J Lipid Res 1990; 31(6): 1089-98.

[35] Haas D, Gan-Schreier H, Langhans CD, et al. Differential diagnosis in patients with suspected bile acid synthesis defects. World J Gastroenterol 2011; 14;18(10):1067-76.

[36] Monte MJ, Marin JJ, Antelo A, et al. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol 2009; 21;15(7):804-16.

[37] Donazzolo E, Gucciardi A, Mazzier D, et al. Improved synthesis of glycine, taurine and sulfate conjugated bile acids as reference compounds and internal standards for ESI-MS/MS urinary profiling of inborn errors of bile acid synthesis. Chem Phys Lipids 2017; 204:43-56.

[38] Clayton PT. Disorders of bile acid synthesis. J Inherit Metab Dis 2011; 34(3):593-604.

[39] Hong J, Oh SH, Yoo HW, et al. Complete Recovery of Oxysterol 7α-Hydroxylase Deficiency by Living Donor Transplantation in a 4-Month-Old Infant: the First Korean Case Report and Literature Review. J Korean Med Sci 2018; 22;33(51): e324.

[40] Clayton PT, Leonard JV, Lawson AM, et al. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. J Clin Invest. 1987; 79: 1031–1038.

[41] Cheng JB, Jacquemin E, Gerhardt M, et al. Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J Clin Endocrinol Metab. 2003;88(4):1833–1841.

[42] Subramaniam P, Clayton PT, Portmann BC, et al. Variable clinical spectrum of the most common inborn error of bile acid metabolism-3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency. J Pediatr Gastroenterol Nutr. 2010; 50: 61–66.

[43] Jahnel J, Zöhrer E, Fischler B, et al. Attempt to determine the prevalence of two inborn errors of primary bile acid synthesis: results of a European survey. J Pediatr Gastroenterol Nutr. 2017; 64: 864–868.

[44] Matarazzo L, Martelossi S, Chiaffoni GP, et al. A Familial non-itching cholestasis. Dig Liver Dis 2014;46: 105-6.

[45] Setchell KDR, O’Connell NC. Disorders of bile acid synthesis and metabolism: a metabolic basis for liver disease in children. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. Third Edition ed Cambridge University Press; 2007; 736–766.

[46] Bove KE, Daugherty CC, Tyson W, et al. Bile acid synthetic defects and liver disease. Pediatr Dev Pathol 2000; 3:1-16.

[47] Drury JE, Mindnich R, Penning TM. Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency. J Biol Chem. 2010; 285: 24529–24537.

[48] Kondo KH, Kai MH, Setoguchi Y, et al. Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme. Eur J Biochem. 1994; 219: 357–363.

[49] Seki Y, Mizuochi T, Kimura A, et al. Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene: diagnosis and bile acid profiles during chenodeoxycholic acid treatment. J Inherit Metab Dis. 2013;36(3):565-573.

[50] Ueki I, Kimura A, Nishiyori A, et al. Neonatal cholestatic liver disease in an Asian patient with a homozygous mutation in the oxysterol 7alpha‐hydroxylase gene. J Pediatr Gastroenterol Nutr. 2008; 46: 465‐469.

[51] Craigen WJ. Chapter 160. Disorders of bile acid synthesis. In: Kline MW, editor. Rudolph’s Pediatrics. 23rd ed. New York, NY: McGraw-Hill Education; 2018.

[52] Heubi JE, Setchell KDR, Bove KE. Inborn Errors of Bile Acid Metabolism. Semin Liver Dis. 2007; 27: 282–294.

[53] Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002; Jul; 110(1):109-17.

[54] Mignarri A, Gallus GN, Dotti MT, et al. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2014; 37:421–429.

[55] Shimazu K, Kuwabara M, Yoshii M, et al. Bile alcohol profiles in bile, urine, and feces of a patient with cerebrotendinous xanthomatosis. J. Biochem, 1986; 99(2), 477-483.

[56] Menkes JH, Schimschock JR, Swanson PD. Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol. 1968; Jul;19(1):47-53.

[57] Salen G, Shefer S, Tint G S, et al. Biosynthesis of bile acids in cerebrotendinous xanthomatosis: relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26. J Clin Invest. 1985; 76 744-751.

[58] Koopman BJ, van der Molen JC, Wolthers BG, et al. Capillary gas chromatographic determination of cholestanol/cholesterol ratio in biological fluids: its potential usefulness for the follow-up of some liver diseases and its lack of specificity in diagnosing CTX (cerebrotendinous xanthomatosis). Clin Chim Acta. 1984; 137 305-315.

[59] Ferdinandusse S, Denis S, IJlst L, et al. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res. 2000; 41: 1890–1896.

[60] Ferdinandusse S, Overmars H, Denis S, et al. Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency. J Lipid Res. 2001; 42: 137–141.

[61] Suchy FJ, Sokol RJ, Balistreri WF. Liver Disease in Children. (3rd ed.), Cambridge University Press, Cambridge. 2007; 736-766.

[62] Sjovall J. Dietary glycine and taurine conjugation in man. Proc Soc Exp Biol Med. 1959; 100 676-678.

[63] Hubbard B, Doege H, Punreddy S, et al. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology, 130, 2006; 1259-1269.

[64] Steinberg SJ, Mihalik SJ, Kim DG, et al. The human liver-specific homolog of very long-chain acyl-CoA synthetase is cholate: CoA ligase. J. Biol. Chem, 275, 2000; 15605-15608.

[65] Chong CP, Mills PB, McClean P, et al. Bile acid-CoA ligase deficiency--a new inborn error of bile acid metabolism. J Inherit Metab Dis. 2012 May;35(3):521-530.

[66] Davit-Spraul A, Gonzales E, Baussan C, et al. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009; 4:1.

[67] Cavestro GM, Frulloni L, Cerati E, et al. Progressive familial intrahepatic cholestasis. Acta Biomed. 2002;73:53–56.

[68] Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol, 4:2014; 25-36.

[69] Arnell H, Nemeth A, Annerén G, et al. Progressive familial intrahepatic cholestasis (PFIC): evidence for genetic heterogeneity by exclusion of linkage to chromosome 18q21-q22. Hum Genet. 1997; 100: 378–381.

Kaynak Göster

153 96

Arşiv
Sayıdaki Diğer Makaleler

Evaluation of cancer related missense mutations in CENPH

CEREN SUCULARLI

Infant Acute Lymphoblastic Leukemia with Atypical Presentation

İnci YAMAN BAJİN, Yılmaz YILDIZ, Şenol AKIN, Selin AYTAÇ, Şule ÜNAL, Barış KUŞKONMAZ, Mualla ÇETİN, Serap SİVRİ, FATMA GÜMRÜK

Better Outcomes with Minimally Invasive Thyroidectomy than Conventional Thyroidectomy

Nilda SÜTAY SÜSLÜ, Çağrı KÜLEKÇİ, Selçuk DAĞDELEN, Nafiye YILDIZ, AYŞE TOMRİS ERBAŞ

Mid-Term Outcomes of Percutaneous Treatment of Superficial Femoral Artery Total Occlusions: Single Center Experience

AHMET HAKAN ATEŞ, AYSU BAŞAK ÖZBALCI, Selim KUL, Mustafa YENERÇAĞ, Metin OKŞUL, UĞUR ARSLAN

Pain Management of Multiple Rib Fractures based on Early Reduction and Fixation in Patients without Intensive Care Unit

İsmail AĞABABAOĞLU, ÖZGÜR ÖMER YILDIZ, Filiz Banu ÇETİNKAYA ETHEMOGLU, Yavuz Selim SANİOĞLU

The Difference in Clinical and Prognostic Features Between De Novo and Recurrent Her2-Positive Metastatic Breast Cancer Patients

Yusuf ACIKGOZ, Yakup ERGÜN, Gökhan UÇAR, Merve DİRİKOÇ, Doğan UNCU

Pretibial Edema Strain Ratio Obtained by Elastography Can Be Used in Differential Diagnosis of Patients with Chronic Heart Failure and Nephrotic Syndrome

DERYA DEMİRTAŞ, Burçak ÇAKIR PEKÖZ, Mehmet KÜÇÜKOSMANOĞLU

Biliary Atresia Splenic Malformation Syndrome: A Single Center Experience

Önder ÖZDEN, Şeref Selçuk KILIÇ, Murat ALKAN, Gökhan TÜMGÖR, Recep TUNCER

Pathways and Inborn Errors of Bile Acid Synthesis

UFUK BOZKURT OBUZ, İNCİLAY LAY